Latest Oncology News

Experts Review Key Data  From ESMO Congress 2021

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Brittany Lovely

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021

Caroline Seymour

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Novel Therapies Propel the Paradigms of Breast and Gynecologic Cancers Forward

Novel Therapies Propel the Paradigms of Breast and Gynecologic Cancers Forward

November 28th 2021

Jessica Hergert

Panelists discuss the latest advances in targeting HER2-positive breast cancer, the rapidly evolving landscape of triple-negative breast cancer, the role of maintenance therapy in ovarian cancer, and recent updates in the treatment of patients with endometrial and cervical cancers.

Investigators Set Their Sets on Novel Targets in Genitourinary Malignancies

Investigators Set Their Sets on Novel Targets in Genitourinary Malignancies

November 27th 2021

Caroline Seymour

Manojkumar Bupathi, MD, MS, shares the main highlights from the meeting, which centered on frontline, second, and later-line treatment of metastatic urothelial carcinoma and metastatic renal cell carcinoma.

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

November 26th 2021

Caroline Seymour

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

Latest Oncology Videos

All Oncology News

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

January 13th 2021

Richard M. Stone, MD, Dana-Farber Cancer Institute

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

January 13th 2021

Richard M. Stone, MD, Dana-Farber Cancer Institute

Prognostic Factors Which Impact ALL Management

January 13th 2021

Richard M. Stone, MD, Dana-Farber Cancer Institute

Dr. Chalabi on the Role of MSI Testing in CRC

January 13th 2021

Myriam Chalabi, MD

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Dr. Sullivan on Sequencing Targeted Therapy and Immunotherapy in Melanoma

January 13th 2021

Ryan Sullivan, MD

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Dr. Janjigian on the Importance of Routine HER2 Testing in Gastric/GEJ Cancer

January 13th 2021

Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Dr. Fonseca on the Emergence of MRD in Multiple Myeloma

January 13th 2021

Rafael Fonseca, MD

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

Dr. Schweizer on the Results of the HERO Trial in Prostate Cancer

January 13th 2021

Michael Schweizer, MD

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Dr. DeAngelo on the Utility of Moxetumomab Pasudotox in HCL

January 13th 2021

Daniel J. DeAngelo, MD, PhD

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Dr. Naumann on the TOPACIO Trial With Pembrolizumab/Niraparib in Ovarian Cancer

January 12th 2021

R. Wendel Naumann, MD

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

Christina T. Loguidice

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Palbociclib Fails to Improve PFS in HR+, AI-Resistant Metastatic Breast Cancer

January 12th 2021

Kristi Rosa

January 12, 2021 - Palbociclib in combination with endocrine therapy failed to result in a statistically significant improvement in progression-free survival over capecitabine in patients with hormone receptor–positive metastatic breast cancer who were resistant to aromatase inhibitors.

Adjuvant Oxaliplatin Added to Fluoropyridine Improves Survival in Stage III MSI-High Colon Cancer

January 12th 2021

Wayne Kuznar

The addition of adjuvant oxaliplatin to fluoropyridine improves overall survival and disease-free survival compared with fluoropyridine alone in patients with stage III colon cancer with microsatellite instability.

Johnson Assumes Director Post of Lung Cancer Research at Sarah Cannon Research Institute

January 12th 2021

Gina Mauro

Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.

Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and Teacher

January 12th 2021

Dean F. Bajorin, MD, MSKCC

Long before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.

See All News